Baseline fluid biomarkers in a phase 2 clinical trial in Parkinson’s Disease
Objective: To evaluate baseline CSF and blood-based biomarkers of pathology in early-stage Parkinson’s Disease (PD) participants in the phase 2 clinical trial PASADENA. Background: Observational…PDQ-39 predicts quality of life improvement following neurostimulation for Parkinson’s disease: Prospective observational study
Objective: The primary outcome was assessing QoL of a cohort of patients with PD before and after undergoing DBS surgery, measured using PDQ-39 questionary. Secondary…Detecting clinical fluctuations in chronic biomarker recordings: experiences with chronic subthalamic peak beta band recordings in a large Parkinson’s disease patient cohort
Objective: Since the understanding of electrophysiological biomarker dynamics during every-day activities is crucial for adaptive deep brain stimulation (aDBS), this study aims to investigate characteristics…Subjective cognitive decline as predictor of objective cognitive decline in Parkinson’s patients
Objective: The present study cross-sectionally and longitudinally explores the predictive value of subjective cognitive decline (SCD) regarding objective cognitive decline in a large clinical sample…Action- and emotion-related language abilities in Slovenian-speaking individuals with Parkinson’s disease – a background normative study
Objective: To prepare action-related (AR) and emotion-related (ER) linguistic stimuli in Slovenian language to test language functions in Parkinson's disease (PD) patients. Background: PD patients…RNA editing contributes to the inflammatory astrocytic response in Parkinson’s disease.
Objective: 1) Using an IPSC derived cell model to explore astrocytic responses alone and cocultured neurons to alpha-synuclein oligomer (αsynO) treatment.2) Determine the extent to…Combination of clinical and gait measures to classify fallers and non-fallers in Parkinson’s disease
Objective: To identify clinical and objective gait measures that best discriminate fallers from non-fallers in Parkinson’s disease (PD), with suggestions of optimal cutoff scores Background:…Longitudinal CSF measurements of alpha-synuclein, amyloid beta and tau in Parkinson disease
Objective: To evaluate whether cerebrospinal fluid (CSF) levels of alpha synuclein (Asyn), amyloid beta (Aβ) and tau change with disease progression and to evaluate whether…Exercise and levodopa metabolism in Parkinson disease
Objective: The aim of our paper was to assess if standard physical exercise may change pharmacokinetics of levodopa/benserazide in patients with and without prior exposure…Screening risk of falls in Parkinson’s disease population living in underserved areas
Objective: To verify the feasibility of the Balance-App to assess the risk of falls in the PD population living in underserved areas. Background: The screening…
- « Previous Page
- 1
- …
- 177
- 178
- 179
- 180
- 181
- …
- 338
- Next Page »